Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
Tonini
G
G
Bizzarri
C
C
Bonfanti
R
R
Vanelli
M
M
Cerutti
F
F
Faleschini
E
E
Meschi
F
F
Prisco
F
F
Ciacco
E
E
Cappa
M
M
Torelli
C
C
Cauvin
V
V
Tumini
S
S
Iafusco
D
D
Barbetti
F
F
D019943:Amino Acid Substitution; D001786:Blood Glucose / Q000378:metabolism; D002648:Child; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D007328:Insulin / Q000627:therapeutic use*; D009154:Mutation; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D016896:Treatment Outcome
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D024661:Potassium Channels, Inwardly Rectifying; D013453:Sulfonylurea Compounds